{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:56:18Z","timestamp":1789480578440,"version":"build-2803163510"},"reference-count":17,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Zanubrutinib is a next-generation covalent Bruton tyrosine kinase (BTK) inhibitor designed to provide complete and sustained BTK occupancy for efficacy across disease-relevant tissues, with fewer off-target effects than other covalent BTK inhibitors. In the phase 3 ASPEN study (BGB-3111-302), comparable efficacy and a favorable safety profile vs ibrutinib were demonstrated in patients with MYD88 (myeloid differentiation primary response 88)\u2013mutated Waldenstr\u00f6m macroglobulinemia (WM), leading to approval of zanubrutinib for patients with WM. BGB-3111-LTE1 (LTE1) is a long-term extension study to which eligible patients, including patients from comparator treatment arms, could enroll after participation in various parent studies of zanubrutinib to treat B-cell malignancies. Here, safety and efficacy are reported in the 47 patients who transitioned from ibrutinib treatment in ASPEN to zanubrutinib in LTE1. The median time from ibrutinib treatment initiation to LTE1 enrollment was 50.4 months (range, 26-59.3). At median LTE1 study follow-up of 15.3 months (range, 6.0-35.1), 85% of patients in this subgroup remained on zanubrutinib treatment. The median zanubrutinib treatment duration was 15.3 months. Despite advanced and increasing patient age, most ibrutinib treatment-emergent adverse events of interest for BTK inhibitors did not recur or worsen with zanubrutinib. WM disease response was maintained or improved in 44 of 46 efficacy-evaluable patients (96%; n = 2 converted to negative immunofixation). Although limited by sample size and nonrandomized\/ad hoc analyses, data suggest that patients who tolerate ibrutinib may switch to zanubrutinib without compromising safety or efficacy. Long-term follow-up is ongoing. These trials were registered at www.ClinicalTrials.gov as #NCT03053440 and #NCT04170283.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015596","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T19:08:45Z","timestamp":1757444925000},"page":"6538-6546","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenstr\u00f6m macroglobulinemia from the ASPEN study"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4120-2787","authenticated-orcid":false,"given":"Ram\u00f3n","family":"Garc\u00eda-Sanz","sequence":"first","affiliation":[{"name":"1Hematology Department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, FiSGM, Universidad Complutense de Madrid, CIBERONC, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger G.","family":"Owen","sequence":"additional","affiliation":[{"name":"2Hematology Department, St. James\u2019s University Hospital, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1879-8084","authenticated-orcid":false,"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[{"name":"3Hematology Department, Maria Sklodowska-Curie National Research Institute of Oncology, Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"4Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"McCarthy","sequence":"additional","affiliation":[{"name":"5Hematology Department, Royal Bournemouth Hospital, Bournemouth, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Cull","sequence":"additional","affiliation":[{"name":"6Hematology Department, Sir Charles Gairdner Hospital, Nedlands, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0308-6458","authenticated-orcid":false,"given":"Stephen S.","family":"Opat","sequence":"additional","affiliation":[{"name":"7Hematology Department, Lymphoma Research Group, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9490-7532","authenticated-orcid":false,"given":"Jorge J.","family":"Castillo","sequence":"additional","affiliation":[{"name":"8Hematology Department, Bing Center for Waldenstr\u00f6m Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8904-3802","authenticated-orcid":false,"given":"Marie Jos\u00e9","family":"Kersten","sequence":"additional","affiliation":[{"name":"9Hematology Department, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3566-8847","authenticated-orcid":false,"given":"Bj\u00f6rn E.","family":"Wahlin","sequence":"additional","affiliation":[{"name":"10Hematology Department, Karolinska Universitetssjukhuset Solna, Solna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2644-1050","authenticated-orcid":false,"given":"Sebastian","family":"Grosicki","sequence":"additional","affiliation":[{"name":"11Hematology Department, School of Public Health, Medical University of Silesia, Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radha","family":"Prathikanti","sequence":"additional","affiliation":[{"name":"12BeOne Medicines Ltd, San Carlos, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Tian","sequence":"additional","affiliation":[{"name":"12BeOne Medicines Ltd, San Carlos, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Allewelt","sequence":"additional","affiliation":[{"name":"12BeOne Medicines Ltd, San Carlos, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aileen Cleary","family":"Cohen","sequence":"additional","affiliation":[{"name":"12BeOne Medicines Ltd, San Carlos, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9759-5017","authenticated-orcid":false,"given":"Constantine S.","family":"Tam","sequence":"additional","affiliation":[{"name":"13Hematology Department, Alfred Hospital and Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"issue":"11","key":"2025122308511228100_bib1","doi-asserted-by":"crossref","first-page":"e827","DOI":"10.1016\/S2352-3026(20)30224-6","article-title":"Consensus treatment recommendations from the tenth International Workshop for Waldenstrom macroglobulinaemia","volume":"7","author":"Castillo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"17","key":"2025122308511228100_bib2","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton\u2019s tyrosine kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J Med Chem"},{"issue":"4","key":"2025122308511228100_bib3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"issue":"33","key":"2025122308511228100_bib4","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1200\/JCO.23.00775","article-title":"ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma","volume":"41","author":"Zinzani","year":"2023","journal-title":"J Clin Oncol"},{"issue":"21","key":"2025122308511228100_bib5","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.2021014162","article-title":"Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study","volume":"139","author":"Song","year":"2022","journal-title":"Blood"},{"issue":"23","key":"2025122308511228100_bib6","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1158\/1078-0432.CCR-21-1704","article-title":"The MAGNOLIA trial: zanubrutinib, a next-generation Bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed\/refractory marginal zone lymphoma","volume":"27","author":"Opat","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2025122308511228100_bib7","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol"},{"issue":"18","key":"2025122308511228100_bib8","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"key":"2025122308511228100_bib9","volume-title":"Brukinsa (zanubrutinib) [package insert (USA)]","year":"2024"},{"issue":"1","key":"2025122308511228100_bib10","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41408-023-00902-x","article-title":"Zanubrutinib: past, present, and future","volume":"13","author":"Tam","year":"2023","journal-title":"Blood Cancer J"},{"issue":"33","key":"2025122308511228100_bib11","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1200\/JCO.22.02830","article-title":"Zanubrutinib versus ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: final analysis from the randomized phase III ASPEN study","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025122308511228100_bib12","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/S2352-3026(22)00320-9","article-title":"Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study","volume":"10","author":"Shadman","year":"2023","journal-title":"Lancet Haematol"},{"issue":"26","key":"2025122308511228100_bib13","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1182\/blood.2024024667","article-title":"Sustained benefit of zanubrutinib vs ibrutinib in patients with R\/R CLL\/SLL: final comparative analysis of ALPINE","volume":"144","author":"Brown","year":"2024","journal-title":"Blood"},{"issue":"23","key":"2025122308511228100_bib14","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1182\/bloodadvances.2020003010","article-title":"Zanubrutinib for the treatment of MYD88 wild-type Waldenstrom macroglobulinemia: a substudy of the phase 3 ASPEN trial","volume":"4","author":"Dimopoulos","year":"2020","journal-title":"Blood Adv"},{"key":"2025122308511228100_bib15","unstructured":"National Cancer Institute\n          . Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Accessed 15 April 2024. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf."},{"issue":"2","key":"2025122308511228100_bib16","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/bjh.12102","article-title":"Response assessment in Waldenstr\u00f6m macroglobulinaemia: update from the VIth International Workshop","volume":"160","author":"Owen","year":"2013","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"2025122308511228100_bib17","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1182\/blood-2024-199276","article-title":"Long-term clinical outcomes in patients with Waldenstr\u00f6m macroglobulinemia (WM) who received zanubrutinib in the phase 3 ASPEN study: a report from the zanubrutinib extension study","volume":"144","author":"D\u2019Sa","year":"2024","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/24\/6538\/2475772\/blooda_adv-2024-015596-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/24\/6538\/2475772\/blooda_adv-2024-015596-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T13:51:20Z","timestamp":1766497880000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/24\/6538\/547194\/Outcomes-after-transition-from-ibrutinib-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":17,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025,12,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015596","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,23]]},"published":{"date-parts":[[2025,12,15]]}}}